UPDATE: The deadline is passed (21 February). For further information, please contact executive@iqnpath.org
IQN Path invites expressions of interest from all EQA provider members to collaborate to develop and
deliver EQA to assess the standard of testing circulating free tumour DNA (cfDNA) for multiple
biomarkers in plasma.
The first IQN Path supported activity was a collaboration between EQA providers (AIOM, EMQN, ESP
EQA and GenQA) to provide an EQA to assess the standard of testing for the presence of cfDNA in
plasma with the purpose of promoting high quality testing. There have been three EQA rounds
successfully delivered; the first to determine the suitability of manufactured material and the
subsequent rounds for clinical testing laboratories to assess the standard of cfDNA plasma testing and
reporting of the presence of EGFR mutations.
Laboratories continue to request the delivery of a cfDNA plasma testing for EGFR mutations and new
developments in the field of cfDNA plasma testing for a more extensive range of biomarkers has
initiated the demand from key stakeholders (e.g. pharmaceutical companies) to extend the EQA remit
to include more targets.
This invitation is to develop two EQA pilots under the collaborative umbrella of IQN Path for the
testing of cfDNA in plasma for a range of pathogenic single nucleotide variants (SNVs) and gene
fusions in multiple genes e.g. EGFR, KRAS, NRAS, BRAF and PIK3CA.
Please send your expression of interest to executive@IQNPath.org and office@IQNPath.org and you
will be contacted with further information.
According to the project timeline, we’d be grateful hearing from those of you who are interested in
participating and/or supporting the project by 21 February.
We look forward to delivering this next new IQN Path initiative.
Prof Sandi Deans, Director, GenQA